Printer Friendly

DR. D. WALTER COHEN JOINS ATRIX LABORATORIES BOARD OF DIRECTORS

 DR. D. WALTER COHEN JOINS ATRIX LABORATORIES BOARD OF DIRECTORS
 FORT COLLINS, Colo., July 23 /PRNewswire/ -- Atrix Laboratories, Inc. (NASDAQ: ATRX) today announced the appointment of Dr. D. Walter Cohen, D.D.S. to its board of directors.
 Cohen is currently the president of the Medical College of Pennsylvania and has been a clinical professor of dental research at the college since 1973. He was the dean at the University of Pennsylvania's School of Dental Medicine from 1972 to 1983.
 Cohen has published extensively and has contributed to several classical textbooks in the area of periodontology.
 Among Cohen's many honors and credits are: the Boston University Citation for Outstanding Contribution to Periodontics; Gold Medal Award, American Academy of Periodontology; Super Achievers Award, Juvenile Diabetes Foundation; and honorary doctorates to Hebrew University of Jerusalem, University of Athens, University of Detroit, and University of Louis Pasteur in Strasborg, France.
 Cohen is a consultant to the surgeon general, U.S. Public Health Service and has consulted the U.S. Naval Dental School, Walter Reed Army Medical Center, and the U.S. Air Force.
 He served on the American Board of Periodontology from 1966-1972, when he retired as chairman in 1972.
 Dr. G. Lee Southard, Atrix's president and CEO, stated: "We are extremely pleased to welcome Walter Cohen to our board of directors. Dr. Cohen has served on our scientific board in the past and has been and will continue to be an active contributor to our research and development efforts, as well as our clinical studies. Walter Cohen is world renown and is well-respected within the periodontal community. We look forward to the invaluable expertise he will lend us."
 Cohen commented that he is pleased to continue working with Atrix on its periodontal product development. "I am an enthusiastic supporter of Atrix's work in the treatment of chronic adult periodontal disease via its ATRIGEL(TM) drug delivery system and ATRISORB(TM), the guided tissue regeneration product to enhance regeneration following gum flap surgery. I have full confidence in management's ability to accomplish the goals they have set for the company and I am delighted to be an active member of Atrix's board of directors."
 Atrix Laboratories is a drug delivery company with the ATRIGEL(TM) system, a unique, proprietary drug delivery technology that is biodegradable and can be utilized for a broad range of human and animal application, including the treatment of periodontal disease.
 -0- 7/23/92
 /CONTACT: Dale Clift, VP and director-finance and operations of Atrix Laboratories, 303-482-5868, or Susan Sherman of Cameron Associates, 212-644-9560, for Atrix Laboratories/
 (ATRX) CO: Atrix Laboratories Inc. ST: Colorado IN: MTC SU: PER


PS-CK -- NY071 -- 2542 07/23/92 12:45 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 23, 1992
Words:447
Previous Article:ARCO CHEMICAL REPORTS SECOND QUARTER 1992 RESULTS
Next Article:ANDREW SETS THIRD-QUARTER AND NINE-MONTH SALES AND INCOME RECORDS
Topics:


Related Articles
DR. CHARLES P. COX JOINS ATRIX LABORATORIES AS VICE PRESIDENT OF PRODUCT DEVELOPMENT
ATRIX LABORATORIES AND COLGATE PALMOLIVE TO END MARKETING AGREEMENT
ATRIX ANNOUNCES PROMOTION OF MS. ELAINE GAZDECK TO V.P. OF REGULATORY AFFAIRS/QUALITY ASSURANCE
Atrix Submits New Drug Application to FDA for Major Advance In Periodontal Therapy
Atrix To Continue Development of Cancer Therapy
Atrix Laboratories Acquires ViroTex; Gains Four Short-Acting Drug Delivery Technologies.
ATRIX REPORTS SUCCESSFUL RESULTS FOR PROSTATE CANCER TREATMENT.
Atrix Forms Partnership With Elan Focused on Oncology And Pain Management Products.
ATRIX/ELAN SIGN PACT FOR ONCOLOGY AND PAIN MANAGEMENT PRODUCTS.
Atrix and Novartis Company - Geneva Pharmaceuticals - Form Collaboration to Develop Prescription Generics.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters